跳至主要内容
临床试验/NCT00222092
NCT00222092已完成不适用

Effect of Octreotide, Somatostatin, Pentoxyfilline or Placebo in the Prevention and the Course of Post-ERCP Pancreatitis and Study of Molecular Markers in Post-ERCP Pancreatitis

University of Ioannina1 个研究点 分布在 1 个国家目标入组 300 人开始时间: 2005年9月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
300
试验地点
1

研究概览

简要总结

Octreotide, somatostatin and pentoxyfilline commercially available drugs that are used in various clinical situations. They are safe and known for years. Octreotide and somatostatin have been used in many studies for the prophylaxis and treatment of pancreatitis and post-ERCP pancreatitis, while pentoxyfilline has shown effect on patients with alcoholic hepatitis, obstructive vasculitis etc. The aim of the study is to evaluate the efficacy of any of those treatments for the prophylaxis and treatment of post-ERCP pancreatitis. In addition some molecular markers of acute and chronic inflammation will be measured before and after the endoscopic procedures according to the study protocol.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • patients undergoing endoscopic retrograde cholangiopancreatography

排除标准

  • children, pregnant or breastfeeding women
  • patients with coagulation disorders
  • inability to access the papilla of Vater due to technical difficulties (previous surgery, malignant obstruction)

研究者

申办方类型
Other

研究点 (1)

Loading locations...

相似试验

Somatostatin, Octreotide, Pentoxyfilline in the... | 临床试验